BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
413 results:

  • 1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Successful treatment of a Case of Crescentic Glomerulonephritis in a Patient with Primary Peritoneal Carcinoma: A case report.
    Zribi A; Nagy A; Riyami MA; Burney IA
    Sultan Qaboos Univ Med J; 2024 Feb; 24(1):119-122. PubMed ID: 38434475
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
    Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
    Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung cancer and High-Grade Serous ovarian Carcinoma: A Case Report.
    Lin J; Welch S; Sanatani M; Ramadan S
    Curr Oncol; 2024 Jan; 31(1):558-565. PubMed ID: 38275832
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. 8-Br-cGMP suppresses tumor progression through egfr/PLC γ1 pathway in epithelial ovarian cancer.
    Wu M; Mu C; Yang H; Wang Y; Ma P; Li S; Wang Z; Lan T
    Mol Biol Rep; 2024 Jan; 51(1):140. PubMed ID: 38236447
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in egfr Stabilization and ovarian cancer Cell Invasion.
    Xia T; Ye F; Zhao W; Min P; Qi C; Wang Q; Zhao M; Zhang Y; Du J
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203692
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pan-egfr Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in ovarian cancer SKOV3-TR Cells.
    Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
    Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Increase in creatinine levels associated with niraparib maintenance therapy in ovarian cancer.
    Takahashi Y; Taguchi M; Tamura K; Shinohara M; Koyanagi T; Takahashi S; Taneichi A; Takei Y; Saga Y; Fujiwara H
    J Obstet Gynaecol Res; 2024 Mar; 50(3):501-507. PubMed ID: 38115203
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report.
    Biben E; Menon L; Gokden N; Spond MF; Eichhorn JM; Aydin AM
    BMC Urol; 2023 Dec; 23(1):204. PubMed ID: 38066479
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells.
    Chen Y; He Z; Yang S; Chen C; Xiong W; He Y; Liu S
    J Transl Med; 2023 Dec; 21(1):886. PubMed ID: 38057816
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Modulatory effect of pomegranate peel extract on key regulators of ovarian cellular processes
    Kolesarova A; Baldovska S; Kohut L; Vasicek J; Ivanisova E; Arvay J; Duracka M; Roychoudhury S
    Front Endocrinol (Lausanne); 2023; 14():1277155. PubMed ID: 38027211
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Expression of egfr, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The Network Pharmacology Analysis of Tonifying Yang Formula for the treatment of Diminished ovarian Reserve.
    Ma Q; Wu X; Chen D; Li W; Wu J; Shen M; Ye C; Tan Y; Guo Q
    Altern Ther Health Med; 2024 Mar; 30(3):176-184. PubMed ID: 37883761
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. egfr-targeted humanized single chain antibody fragment functionalized silica nanoparticles for precision therapy of cancer.
    Wu H; Ding X; Chen Y; Cai Y; Yang Z; Jin J
    Int J Biol Macromol; 2023 Dec; 253(Pt 8):127538. PubMed ID: 37866562
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.
    Di Agostino S; Canu V; Donzelli S; Pulito C; Sacconi A; Ganci F; Valenti F; Goeman F; Scalera S; Rollo F; Bagnato A; Diodoro MG; Vizza E; Carosi M; Rufini B; Federici O; Giofrè M; Carboni F; Muti P; Ciliberto G; Strano S; Valle M; Blandino G
    Cell Death Dis; 2023 Aug; 14(8):535. PubMed ID: 37598177
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Ligand-installed polymeric nanocarriers for combination chemotherapy of egfr-positive ovarian cancer.
    Xi X; Lei F; Gao K; Li J; Liu R; Karpf AR; Bronich TK
    J Control Release; 2023 Aug; 360():872-887. PubMed ID: 37478915
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Activation of invasion by oncogenic reprogramming of cholesterol metabolism via increased NPC1 expression and macropinocytosis.
    Skorda A; Lauridsen AR; Wu C; Huang J; Mrackova M; Winther NI; Jank V; Sztupinszki Z; Strauss R; Bilgin M; Maeda K; Liu B; Luo Y; Jäättelä M; Kallunki T
    Oncogene; 2023 Aug; 42(33):2495-2506. PubMed ID: 37420029
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer.
    Hugendieck G; Lettau M; Andreas S; Neumann S; Reinhardt N; Arnold P; Theilig F; Bastian L; Rogmans C; Weimer JP; Flörkemeier I; Wesch D; Arnold N; Maass N; Janssen O; Bauerschlag D; Hedemann N
    J Extracell Vesicles; 2023 Jul; 12(7):e12338. PubMed ID: 37408115
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Mechanism of Marsdenia tenacissima against ovarian cancer based on network pharmacology and experimental verification].
    Hu YJ; Wei LY; Zhao J; Zhu QF; Meng ZY; Meng JJ; Chen JJ; Xu LY; Zhou YY; Han YL
    Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2222-2232. PubMed ID: 37282910
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
    Qian L; Sun R; Xue Z; Guo T
    Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.